{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:29Z","timestamp":1790697929785,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.coph.2022.102257","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:25:25Z","timestamp":1655443525000},"page":"102257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Current and new targets for treating myositis"],"prefix":"10.1016","volume":"65","author":[{"given":"Siamak","family":"Moghadam-Kia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-3111","authenticated-orcid":false,"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102257_sref1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102257_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2022.102257_bib3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A\u00a0controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102257_bib4","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102257_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.coph.2022.102257_bib6","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 11","key":"10.1016\/j.coph.2022.102257_bib7","first-page":"S118","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coph.2022.102257_bib8","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102257_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"10 Suppl","key":"10.1016\/j.coph.2022.102257_bib10","article-title":"A\u00a0consensus hybrid definition using a conjoint analysis is proposed as response criteria for minimal and moderate improvement in adult polymyositis and dermatomyositis clinical trials","volume":"64","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102257_bib11","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coph.2022.102257_bib12","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coph.2022.102257_bib13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2005.045898","article-title":"Rituximab in the treatment of antisynthetase syndrome","volume":"65","author":"Brulhart","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102257_bib14","first-page":"1369","article-title":"Efficacy of rituximab in refractory polymyositis","volume":"32","author":"Lambotte","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","article-title":"Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)","volume":"16","author":"Arlet","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2022.102257_bib16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102257_bib17","first-page":"1864","article-title":"Rituximab for refractory polymyositis: an open-label prospective study","volume":"34","author":"Mok","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A\u00a0pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.coph.2022.102257_bib19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.coph.2022.102257_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir","year":"2014","journal-title":"Respirology"},{"issue":"8","key":"10.1016\/j.coph.2022.102257_bib22","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coph.2022.102257_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102257_bib24","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_bib25","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_bib26","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/medicina57121358","article-title":"Combination therapy with rituximab, tofacitinib and pirfenidone in a patient with rapid progressive interstitial lung disease (RP-ILD) due to MDA5 antibody-associated dermatomyositis: a case report","volume":"57","author":"Yen","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.coph.2022.102257_bib27","article-title":"Myopathy associated with anti-signal recognition particle antibodies with pulmonary involvement and response to rituximab","author":"Mazeda","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.coph.2022.102257_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102257_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coph.2022.102257_bib30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"10.1016\/j.coph.2022.102257_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.coph.2022.102257_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"10.1016\/j.coph.2022.102257_bib34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2022.102257_sref35","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\"ProDERM Study\")","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.coph.2022.102257_bib36","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102257_bib37","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","article-title":"A\u00a0case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?","volume":"53","author":"Kondo","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102257_sref38","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","article-title":"Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis","volume":"60","author":"Zhang","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102257_bib39","doi-asserted-by":"crossref","first-page":"635654","DOI":"10.3389\/fphar.2021.635654","article-title":"The efficacy of tocilizumab in the treatment of patients with refractory immune-mediated necrotizing myopathies: an open-label pilot study","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2022.102257_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9440(10)65141-3","article-title":"Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies","volume":"155","author":"Murata","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2022.102257_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clim.1999.4743","article-title":"Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells","volume":"92","author":"Nagaraju","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coph.2022.102257_bib42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jbspin.2011.03.022","article-title":"Abatacept for treatment of refractory polymyositis","volume":"78","author":"Musuruana","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.coph.2022.102257_bib43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.coph.2022.102257_bib44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/rheumatology\/ket251","article-title":"Successful treatment of refractory anti-signal recognition particle myopathy using abatacept","volume":"53","author":"Maeshima","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102257_bib45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10067-014-2507-4","article-title":"Abatacept as a successful therapy for myositis\u2014a case-based review","volume":"34","author":"Kerola","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.coph.2022.102257_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102257_bib47","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2022.102257_bib48","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102257_bib49","unstructured":"Baechler EC, Bauer JW, Slattery CA, et\u00a0al. An interferon signature in the peripheral Blo6d of dermatomyositis patients is associated with disease activity. Mol Med."},{"key":"10.1016\/j.coph.2022.102257_bib50","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102257_bib51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A\u00a0phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102257_bib52","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102257_sref53","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102257_bib54","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2022.102257_sref55","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_bib56","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RHU.0000000000000807","article-title":"Tofacitinib for the treatment of refractory polymyositis","volume":"25","author":"Babaoglu","year":"2019","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_bib57","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102257_bib58","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102257_bib59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102257_sref60","doi-asserted-by":"crossref","first-page":"S561","DOI":"10.1097\/RHU.0000000000000999","article-title":"Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast","volume":"27","author":"Charlton","year":"2021","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.coph.2022.102257_sref61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1346-8138.16179","article-title":"Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: a phase 1b clinical trial","volume":"49","author":"Konishi","year":"2022","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.coph.2022.102257_bib62","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102257_bib63","doi-asserted-by":"crossref","first-page":"199-200","DOI":"10.1136\/annrheumdis-2019-eular.3397","article-title":"Safety and efficacy of lenabasum in an open-label extension of a phase 2 study of lenabasum in refractory skin-predominant dermatomyositis (DM) subjects","volume":"78","author":"Werth","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:56:59Z","timestamp":1761461819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":63,"alternative-id":["S1471489222000844"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102257","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and new targets for treating myositis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102257"}}